By contrast, Scottish ministers reinvest those payments in the new medicines fund for innovative new treatments. What impact has the NMF had on encouraging pharmaceutical manufacturing companies to invest in Scotland, given that we allow health boards to purchase end-of-life, orphan and ultra-orphan medicines that they might have struggled to justify financially before the fund was established in 2013?